Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 20.6% – Time to Buy?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares shot up 20.6% during mid-day trading on Wednesday . The stock traded as high as $2.88 and last traded at $2.81. 51,176 shares were traded during trading, an increase of 206% from the average session volume of 16,703 shares. The stock had previously closed at $2.33.

Alaunos Therapeutics Stock Down 8.2 %

The company’s 50 day moving average price is $2.44 and its 200 day moving average price is $4.76.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Virtu Financial LLC acquired a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.10% of Alaunos Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 27.72% of the company’s stock.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.